Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024)

Ultragenyx Pharmaceutical (RARE) has disclosed Other financing activities for 5 consecutive years, with $7.0 million as the latest value for Q3 2024.

  • Quarterly Other financing activities rose 24900.0% to $7.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $7.0 million for FY2024, N/A changed from the prior year.
  • Other financing activities for Q3 2024 was $7.0 million at Ultragenyx Pharmaceutical, up from $28000.0 in the prior quarter.
  • The five-year high for Other financing activities was $7.0 million in Q3 2024, with the low at -$147000.0 in Q3 2022.
  • Average Other financing activities over 5 years is $392000.0, with a median of -$72500.0 recorded in 2020.
  • The sharpest move saw Other financing activities tumbled 239.39% in 2021, then soared 24900.0% in 2024.
  • Over 5 years, Other financing activities stood at -$87000.0 in 2020, then plummeted by 63.22% to -$142000.0 in 2021, then surged by 407.04% to $436000.0 in 2022, then plummeted by 93.58% to $28000.0 in 2023, then skyrocketed by 24900.0% to $7.0 million in 2024.
  • According to Business Quant data, Other financing activities over the past three periods came in at $7.0 million, $28000.0, and -$56000.0 for Q3 2024, Q3 2023, and Q2 2023 respectively.